Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine  Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

    (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrUNE4yNTVyIN88US=> M1TNVFEzNTd{IHi= MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHS4dVMzPjF|M{K0Oi=>
Jurkat  MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[wMlEuPTBizszN NXjDVHRbOTJvN{KgbC=> NWH1XZV{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVvIXIJ2OjZzM{OyOFY>
CA46 MWnGeY5kfGmxbjDBd5NigQ>? NWnGb5M2OjEEoNM1US=> MY[0PEBp NE\h[5FqdmO{ZXHz[ZPDqFCWUFyxxsBuWk6DIHX4dJJme3Orb36= NVTYfFhtOjZzM{OyOFY>
Raji  NYOyVWVFTnWwY4Tpc44hSXO|YYm= M3TYe|E2yqEEtV2= MlTlOFghcA>? M13xNolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= MWGyOlE{OzJ2Nh?=
Jurkat  MkHtSpVv[3Srb36gRZN{[Xl? Mm\uN{42yqEEtV2= MnTUOFghcA>? MojEbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w NVHVeJg4OjZzM{OyOFY>
MDA-MB-231 NX2zNWZSTnWwY4Tpc44hSXO|YYm= M1TsRlEwOi53L{Wg{txO MYm0PEBp M3TC[4Rm[3KnYYPld{B1cGViUGTQUlEzKGW6cILld5Nqd25iYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDYEoN88UUA1QMLiaB?= M{T0RVI2QDF5MkK5
MDA-MB-231 NFzjR3dHfW6ldHnvckBCe3OjeR?= NWf5bHpoOS9{LkWvOUDPxE1? M2K1VlQ5KGh? MVvpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCHLXPh[IhmemmwIH3SUmEh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFIvPcLizszN[o9zKDR6wrDo M2nhTFI2QDF5MkK5
MDA-MB-231 NF3IO|JHfW6ldHnvckBCe3OjeR?= NIjqNZIyNzJwNT:1JO69VQ>? NWH3UmtXOjRxNEigbC=> M2DLXIlv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=> M{PWWlI2QDF5MkK5
MCF-7 M1n5UmZ2dmO2aX;uJGF{e2G7 NVXQPY9xOS9{LkWvOUDPxE1? NFPjRpozPC92ODDo NI\GZWhqdmO{ZXHz[ZMhWEGUUDDjcIVifmGpZdMg MVOyOVgyPzJ{OR?=
MDA-MB-231  NUnzXWRETnWwY4Tpc44hSXO|YYm= NXrpSmM{OS9{LkWvOUDPxE1? M{jOXlI1NzR6IHi= M1zFUolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBucVKQQT2xNlQh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFUh|ryP M1;ZflI2QDF5MkK5
A498 Mn7tSpVv[3Srb36gRZN{[Xl? MnqzNVAhyrWP MlPEO|IhcA>? MXjpcoR2[2W|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36= MonsNlU2PjlyOE[=
CaKI-2 MXvGeY5kfGmxbjDBd5NigQ>? NXHET45lOTBiwsXN MnGxO|IhcA>? MUTpcoR2[2W|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36= M1\JeVI2PTZ7MEi2
Ketr-3 NFzNU|lHfW6ldHnvckBCe3OjeR?= M1vXOFExKML3TR?= MX23NkBp M4nYZolv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> MlXZNlU2PjlyOE[=
A253 NETRXpZHfW6ldHnvckBCe3OjeR?= NX[3dXNHOTBiwsXN MV[wMVQh\A>? M{W2R4lv[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsJI9nKHSqZTDNN3LDqGGodHXyJFI1KGh? M1rCfFI2PDh3NUO2
A253 NXLDRplZTnWwY4Tpc44hSXO|YYm= M{LyZ|ExKML3TR?= NGP5V|Q4OiCq NYDZPYY2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJRp\SCPM2KgbY4h[m:2aDDt[Y1jemGwZTDhcoQh[3m2b4PvcIlkKHC{ZYDhdoF1cW:wcx?= NHzqPFEzPTR6NUWzOi=>
A253 NWq4ZopITnWwY4Tpc44hSXO|YYm= M1fne|ExKML3TR?= Mn\nNE01KGR? NYDCXIRNemWmdXPld{B1cGViNT3t[ZRpgWyleYTvd4lv\SClb370[Y51 NETvSGgzPTR6NUWzOi=>
PC3 Ml63SpVv[3Srb36gRZN{[Xl? NF70[W4xNjJizszNxsA> M1XNOlQh\A>? M1zsV4lv[3KnYYPld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyxiU1\SVFEh[W6mIGPMR|ZCOTViY3;tZolv\WRid3n0bEBIW0tzMk[= M2jMUVI2PDd5M{Sw
MCF7 M{TnVGZ2dmO2aX;uJGF{e2G7 M1fDXVAvOyEQvF5CpC=> NVPCb3Y3PCCm NYHYcm46cW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> NIW2XWEzPTR5N{O0NC=>
PC3 NInpVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm3cFYxNjJizszNxsA> NFmwVJM1KGR? NVr4UIlU\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEB1dyB{MD6zKUBkd22kaX7l[EB4cXSqIFfTT|EzPg>? MVKyOVQ4PzN2MB?=
MCF7 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInZfFcxNjNizszNxsA> MlqyOEBl MnfE[IVkemWjc3XzJJRp\SClZXzsJIdzd3e2aDCyOE45LSClb33ibY5m\CC5aYToJGdUUzF{Nh?= MnnMNlU1Pzd|NEC=
BGC-823 MnzESpVv[3Srb36gRZN{[Xl? NIn5c442yqEQvF2= NUC0c3JSPzJiaB?= NVi1RW9Z\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? NF\FNVYzPTR5NUezNy=>
MKN28 MmfwSpVv[3Srb36gRZN{[Xl? MVm1xsDPxE1? MYK3NkBp MnrQ[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NX\5WmZCOjV2N{W3N|M>
SGC-7901 MWDGeY5kfGmxbjDBd5NigQ>? NXfSdZdKPcLizszN MXu3NkBp Mmey[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NXrscZJMOjV2N{W3N|M>
MKN45 MYXGeY5kfGmxbjDBd5NigQ>? M{L3cFXDqM7:TR?= NWfueGhXPzJiaB?= MlXJ[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NYHVTHZ1OjV2N{W3N|M>
BGC-823 NI\3TYdHfW6ldHnvckBCe3OjeR?= M4S2WVXDqM7:TR?= Mnf2O|IhcA>? NVHzPXJW\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> MXKyOVQ4PTd|Mx?=
MKN28 M1\hOWZ2dmO2aX;uJGF{e2G7 NX3ZS5NXPcLizszN Mnz1O|IhcA>? MX3k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M13NVVI2PDd3N{Oz
SGC-7901 MYTGeY5kfGmxbjDBd5NigQ>? MVO1xsDPxE1? M2nYOFczKGh? Mn3U[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= NX:4NYl1OjV2N{W3N|M>
MKN45 NI\zVHZHfW6ldHnvckBCe3OjeR?= M2jucFXDqM7:TR?= NWrLOJFsPzJiaB?= NVfsOVYz\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> NIXZWZIzPTR5NUezNy=>
HREC M{i5W2Z2dmO2aX;uJGF{e2G7 NUTQXXJCPS9zMNMg{txO NGTsTHY1QCCq M4DmWYlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MV:yOVM2Ojd2Nx?=
HRPE MkTMSpVv[3Srb36gRZN{[Xl? M1;KU|UwOTEEoN88US=> NX7JO|A3PDhiaB?= Ml[1bY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUWyOVM2Ojd2Nx?=
HREC NWDVc4hSTnWwY4Tpc44hSXO|YYm= NF\FdoU2NzFywrFOwG0> NX62N3VUPDhiaB?= M3nTRYRwf25vcnXneYxifGW|IH;mJHZGT0ZuIFnDRW0uOSBqbn;0JJBzd3SnaX6gcIV3\WxiaX6gTHJRTSClZXzsd{ktKEmOLUJOtkBld3OnLXTldIVv\GWwdHz5 MYqyOVM2Ojd2Nx?=
HRPE MmfnSpVv[3Srb36gRZN{[Xl? NUS3XItEPS9zMNMg{txO MV[0PEBp NEjRRXFld3ewLYLl[5Vt[XSnczDv[kBXTUeILDDJUE0y|rJuIHHu[EBOVVB{IHTvd4Uu\GWyZX7k[Y51dHl? NFrzbWYzPTN3Mke0Oy=>
MSCs MXvGeY5kfGmxbjDBd5NigQ>? NFXBTngyOCEQvF2= Mn\BNlQhcA>? M{mxOJBzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36= NVfre2pFOjV|NUGzPVU>
HL-60 NETlWWtHfW6ldHnvckBCe3OjeR?= M2ntZVUh|ryP NEm5eGQ4OiCq M1WzPGROW09? M1\QR5Nq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36= MVeyOVMyQTB2OR?=
MV4-11 M3[3WWZ2dmO2aX;uJGF{e2G7 NXS5eo5VPSEQvF2= M3qzbVczKGh? M{DFN2ROW09? MYTzbYdvcW[rY3HueIx6KHWycnXneYxifGW|IGrOSlM5OiCneIDy[ZN{cW:w NVvqRmUxOjV|MUmwOFk>
A2780 M3\SNmZ2dmO2aX;uJGF{e2G7 Mlf4OUDDvU4EoB?= M{fKUFch\A>? MXHpcoNz\WG|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt M2LsblI2Ojl7Nkm0
CP70 M{P3RmZ2dmO2aX;uJGF{e2G7 Mo\aOUDDvU4EoB?= NHf5cXA4KGR? M3PMUYlv[3KnYYPld{BFVkFibXX0bJlt[XSrb36gcIV3\Wx? NFnKcYkzPTJ7OU[5OC=>
A2780 NIe0[m1HfW6ldHnvckBCe3OjeR?= MX61JOK2VcLi MkDMO{Bl M3rCZZdm[WunboOgeIhmKGyndnXsJI9nKG2ndHj5cIF1cW:w NES4fI8zPTJ7OU[5OC=>
CP70 MlK3SpVv[3Srb36gRZN{[Xl? NHX4fIw2KML3TdMg M2fmfVch\A>? M2XTPJdm[WunboOgeIhmKGyndnXsJI9nKG2ndHj5cIF1cW:w MkTINlUzQTl4OUS=
OCM3 NV\3ZYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMlUwOS9{IN88US=> NFKyTY04KGR? M4jPWGROW09? NFXGXpRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnvRNlUyPDZ7OEG=
92.1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTyPGtEOC53L{GvNkDPxE1? MV:3JIQ> NV3mVIhSTE2VTx?= NHHiVXJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4H1UlI2OTR4OUix
OCM1 M2PBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Y[lAvPS9zL{Kg{txO M{XzVlch\A>? MVvEUXNQ MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlTVNlUyPDZ7OEG=
OMM1 NIriOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;lOVAvPS9zL{Kg{txO NEOwV4o4KGR? MoXPSG1UVw>? MnW3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFX0S2QzPTF2Nkm4NS=>
Mel 285 MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPzNE42NzFxMjFOwG0> NU\4cItbPyCm MkXtSG1UVw>? MmXibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mle3NlUyPDZ7OEG=
Mel 290 M1uxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL1[|YxNjVxMT:yJO69VQ>? NH3jTY84KGR? Ml;WSG1UVw>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MmDTNlUyPDZ7OEG=
OCM3 MkThSpVv[3Srb36gRZN{[Xl? NWHBN5lzOC53L{Gg{txO NHX0[WE1QCCq MnW4SG1UVw>? MX3k[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 M3GyfFI2OTR4OUix
92.1 M2j3V2Z2dmO2aX;uJGF{e2G7 NXrsdohYOC53L{Gg{txO MVG0PEBp MmTCSG1UVw>? NEDyTIZl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 M32zU|I2OTR4OUix
OCM1 MXPGeY5kfGmxbjDBd5NigQ>? NXzKNpZXOC53L{Gg{txO MVu0PEBp MUTEUXNQ MXfk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 M1nSNFI2OTR4OUix
OMM1 NUK3e5VkTnWwY4Tpc44hSXO|YYm= MV[wMlUwOSEQvF2= MmrPOFghcA>? NGDI[I1FVVOR MlLS[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NXPFSotzOjVzNE[5PFE>
Mel 285 MmroSpVv[3Srb36gRZN{[Xl? M4XmZVAvPS9zIN88US=> NIPQUHQ1QCCq MmfpSG1UVw>? MkTL[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MmLmNlUyPDZ7OEG=
Mel 290 NF\0OGFHfW6ldHnvckBCe3OjeR?= MlzwNE42NzFizszN MlvNOFghcA>? NUDBZVlMTE2VTx?= NWH5bZRn\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= M4rvZVI2OTR4OUix
OCM3 M4TaV2Z2dmO2aX;uJGF{e2G7 MkfMNE42NzFizszN NYnEOI15PDhiaB?= MWDEUXNQ NITtOHZl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh MorJNlUyPDZ7OEG=
Mel 290 NFnKWIZHfW6ldHnvckBCe3OjeR?= MmT4NE42NzFizszN M1PsbFQ5KGh? MXrEUXNQ NILOcIRl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh NYX3S|VGOjVzNE[5PFE>
OMM1 MmrOSpVv[3Srb36gRZN{[Xl? MV:wMlUwOSEQvF2= MYC0PEBp MWPEUXNQ MlzL[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> NFX4W4MzPTF2Nkm4NS=>
OCM1 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmfqNE42NzFizszN NIfpbHQ2KGR? M1\aNGROW09? MVTk[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= Mn:zNlUyPDZ7OEG=
92.1 MmXPR4VtdCCYaXHibYxqfHliQYPzZZk> MUCwMlUwOSEQvF2= MnSyOUBl MoTPSG1UVw>? M4q3UoRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u NXjiNmpROjVzNE[5PFE>
OCM1 MXXGeY5kfGmxbjDBd5NigQ>? NWK1e285OC53L{Gg{txO M1HaSVQ5KGh? M{DmNmROW09? MnnJZ4F2e2W|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?= NHjKTVEzPTF2Nkm4NS=>
OCM3 NX\sOGhmTnWwY4Tpc44hSXO|YYm= MoTGNE42NzFizszN NXyxUnlFPDhiaB?= MY\EUXNQ NELKR3Zk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp NVHXV4ZTOjVzNE[5PFE>
92.1 NXe5cWFjTnWwY4Tpc44hSXO|YYm= MoftNE42NzFizszN MnrTOFghcA>? M{[xV2ROW09? MUjjZZV{\XNiZ3zvZoFtKESQQTDofZBwdWW2aInsZZRqd25iYYSgUE0yKHKncHXheEBtd2Or MXuyOVE1Pjl6MR?=
IMR32 M2f6PWZ2dmO2aX;uJGF{e2G7 NVvPPYhOOyEQvF2= NEPLWYk4OiCq NXX6RWl1TE2VTx?= M4K3UYlv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> NEXXS5UzPTFyNEi1NC=>
IMR5-75 NYrXSlRxTnWwY4Tpc44hSXO|YYm= MXqzJO69VQ>? MYq3NkBp NGqwdYJFVVOR NELQUlNqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk> MorqNlUyODR6NUC=
Be(2)-C NHvJRoFHfW6ldHnvckBCe3OjeR?= MXOzJO69VQ>? NInVcok4OiCq NIrpb5RFVVOR MojQbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 M2PUfFI2OTB2OEWw
Bxpc-3 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\2R2k2NzFyIN88US=> NUTZbXpxOjRxNEivO|IhcA>? MXjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBDgHClLUOgZ4VtdHNiaX6geIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5menN? NW[5Zm1WOjVyNkG3N|E>
Bxpc-3 Ml7vRZBweHSxc3nzJGF{e2G7 M1LzcVUwOTBizszN MkHhNlQwPDhxN{KgbC=> NFfGbmNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=> MWKyOVA3OTd|MR?=
Bxpc-3 MVnGeY5kfGmxbjDBd5NigQ>? MVW1M|ExKM7:TR?= MXqyOE81QC95MjDo MmXZ[IVkemWjc3XzJO6zNWOjdHXubY4h\XiycnXzd4lwdiCjZoTldkAzPCCq MkXQNlUxPjF5M{G=
Bxpc-3 NFjMcpVHfW6ldHnvckBCe3OjeR?= M3Xp[|UwOTBizszN MkPiNlQwPDhxN{KgbC=> M1jjXIRm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2= M2DsTVI2ODZzN{Ox
Bxpc-3 M3fnNGZ2dmO2aX;uJGF{e2G7 NYXWc|dQPS9zMDFOwG0> NF3vOJAzPC92OD:3NkBp M1uyfoRwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=> M3zXUVI2ODZzN{Ox
HL-60 M1HObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDOdZkyNjBizszN NYflT5R6PDhiaB?= NUfidXI5e2mpbnnmbYNidnSueTDpcohq[mm2czDIUE03OCClZXzsJIdzd3e2aNMg M{jMelI2ODVzMUG5
HL-60 NYXvdHZDTnWwY4Tpc44hSXO|YYm= NY\pV|dXOS5yIN88US=> MWW0PEBp NY\1R49PcW6lcnXhd4V{KHB{MWfBSlEwS0mSMdMgZY5lKGOjc4Dhd4UuOyCneIDy[ZN{cW:wwrC= NFi1cXQzPTB3MUGxPS=>
HL-60 M3jX[2Z2dmO2aX;uJGF{e2G7 MlH6NU4xKM7:TR?= MlXHOFghcA>? NFXzO4ll\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NI\2Oo8zPTB3MUGxPS=>
HuTu-80  NGO1eGZHfW6ldHnvckBCe3OjeR?= M3\6e|EwPS9zMDFOwG0> MXS0PE84OiCq MX3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX[yOFkxPDB4Mh?=
Caco2  NXPOXlNxTnWwY4Tpc44hSXO|YYm= NXTnO3JFOTBizszN Mm[3OFghcA>? NFy5WXJqdmO{ZXHz[ZMhVlCFMVyxJIV5eHKnc4Ppc44> MV6yOFkxPDB4Mh?=
HepG2  Ml;VSpVv[3Srb36gRZN{[Xl? NFvzS2wxNTJ3IN88US=> NVH4NpN2OjRiaB?= MYfk[YNz\WG|ZYOgd5VjfGmuaYPpck9s\XirbjD0fZBmKDliKGDDV2s6MSCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 MViyOFg2PTZ2Nh?=
HepG2  NEXLZnJHfW6ldHnvckBCe3OjeR?= M4f6clAuOjVizszN MojoNlQhcA>? M3LaS4lv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB? NGnoNpUzPDh3NU[0Oi=>
HepG2  NU\OOm5YTnWwY4Tpc44hSXO|YYm= MYexNEDPxG4EoB?= MWiwMVI1KGh? M1jSS4Rm[3KnYYPld:KhWEOVS{pCpIFv\MLiSF3HR3LDqGW6cILld5Nqd25iYX7kJIlv[3KnYYPld{BNTEyUIHX4dJJme3Orb36gZYZ1\XJiNjDo NXjEXmUxOjR6NUW2OFY>
HepG2  NWL1OlZTTnWwY4Tpc44hSXO|YYm= NIS3V5AyOCEQvH2= MYqyOEBp MX;wdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{ NXfE[XVmOjR6NUW2OFY>
HepG2  MWfGeY5kfGmxbjDBd5NigQ>? NXrWXWNnOTBizszt NHW4VXgzPCCq MV;wdoV3\W62czDTVmVDWCCycn;j[ZN{cW6p MX6yOFg2PTZ2Nh?=
HC45  MVXGeY5kfGmxbjDBd5NigQ>? NYTRToxTPcL3TdMg MlXVOEBl MnHYdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? NWHkO5NkOjR5NkK4NFk>
CNDT2  NUnDU49nTnWwY4Tpc44hSXO|YYm= NGfFV2E2yrWPwrC= MVO0JIQ> NELvbGZz\WS3Y3XzJJRp\SCvZYTofYxifGmxbjDs[ZZmdHNib3[gW2lHOSxiUEG2MEBEYEOOMUSsJG5MYDMkgKOzMEBETEhzLDDMRW1COSxiYX7kJGNVVk6EMR?= NU\ZUWFoOjR5NkK4NFk>
CNDT2  MX;GeY5kfGmxbjDBd5NigQ>? MkCwOeK2VcLi NXTaWIhKPCCm M4TXS4lv[3KnYYPld{Bo\W6nIHX4dJJme3Orb36gc4bDqFeLRkGsJHAyPixiQ1TINUzDqEyDTVGxMOKh[W6mwrDDWG5PSjF? M1vGOlI1PzZ{OEC5
T-cells MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy1M|IxKM7:TR?= MV:wMVQ5KGh? NWj4dYp{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUjkWo4{OjR5NUeyPFM>
CD3+ T-cells MlfmSpVv[3Srb36gRZN{[Xl? MlWwOU8zOCEQvF2= NIXmTIQ1QCCq MmnweZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= NWjnNotmOjR5NUeyPFM>
CD4+ T-cells NUjncm5TTnWwY4Tpc44hSXO|YYm= MVO1M|IxKM7:TR?= M3fJVVQ5KGh? NGDzeZh2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> NVTxSZlrOjR5NUeyPFM>
CD8+ T-cells M2jUOmZ2dmO2aX;uJGF{e2G7 NGKxcWQ2NzJyIN88US=> MlTiOFghcA>? Mnv6eZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= NIrBZnIzPDd3N{K4Ny=>
CD3+ T-cells MUTGeY5kfGmxbjDBd5NigQ>? NWD1VXZyPS9{MDFOwG0> MkKwOFghcA>? M1POfJVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKE[RWGCz Ml;INlQ4PTd{OEO=
CD4+ T-cells Ml\ZSpVv[3Srb36gRZN{[Xl? NEm1OZM2NzJyIN88US=> M3rTU|Q5KGh? NWTUVGpMfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM> M1j6XFI1PzV5Mkiz
CD4+ T-cells NVzlUlhVTnWwY4Tpc44hSXO|YYm= MofHOU8zOCEQvF2= MkL5OFghcA>? MXHy[YR2[2W|IGTCSXQyyqCvUl7BJIV5eHKnc4Ppc44> MV2yOFc2PzJ6Mx?=
CD4+ T-cells NEnyO4xHfW6ldHnvckBCe3OjeR?= NWrh[Hp4PS9{MDFOwG0> NXvI[YI4PDhiaB?= NIDsSIN2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\sLiUl;S{tN1yqB? M3:zeVI1PzV5Mkiz
CD4+ T-cells MX3GeY5kfGmxbjDBd5NigQ>? MojXOU8zOCEQvF2= MYi0PEBp MVTpcohq[mm2czDt[Y1wenliVD3j[Yxtew>? MVSyOFc2PzJ6Mx?=
CD8+ T-cells MV;GeY5kfGmxbjDBd5NigQ>? MnHmOU8zOCEQvF2= NHrBboM1QCCq MVjpcohq[mm2czDt[Y1wenliVD3j[Yxtew>? Mkj6NlQ4PTd{OEO=
CD3+ T-cells MlLRSpVv[3Srb36gRZN{[Xl? NYe2Rol[PSEQvF2= MlvMOFghcA>? MY\y[YR2[2W|IHzvcocufGW{bTDt[Y1wenliY3XscEBxcGWwb4T5dIU> NIO1eoIzPDd3N{K4Ny=>
U937 NX3qRWo3SXCxcITvd4l{KEG|c3H5 NVftSoNROTBizszN NYrkXpFQPzJiaB?= Mnn0bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M2e3OFI1PjhyOE[1
HL-60 MmDyRZBweHSxc3nzJGF{e2G7 NVP2[Zk5OTBizszN MlfRO|IhcA>? NEXNS3BqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NWX5dJhyOjR4OEC4OlU>
MCF7 M2jsV2Z2dmO2aX;uJGF{e2G7 M2jaUVUh|ryP NFPpVm41QCCqwrC= NUj6WHp6\Gm|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN? MWCyOFY{OzN3MB?=
MCF7 MkG4SpVv[3Srb36gRZN{[Xl? M2\xflExKM7:TR?= M3;Eb|I1KGkEoB?= MWLpcoR2[2W|IITo[UBkdGWjdnHn[UBw\iClYYPwZZNmKDdiYX7kJHBCWlEEoB?= NYC3fJpGOjR4M{OzOVA>
MCF7 NWnvN5dQTnWwY4Tpc44hSXO|YYm= MVew5qCUOC53IN88UeKh MYS3JIQ> M1PafIlvcGmkaYTzJJRp\SCpcn;3eIghVUOILUegeJVud3K|cHjldoV{KGmwIIP1d5BmdnOrb36gZ5VtfHW{ZYRCpC=> M1u2eVI1PjN|M{Ww
MCF7 MYnGeY5kfGmxbjDBd5NigQ>? M1LxfVAvPSEQvF5CpC=> MlTQNVQh\A>? MWry[YR2[2W|IITo[UB{cXqnIH;mJG1ETi15IHPvcI9vcWW|IHXtZoVl\GWmIHnuJJNw\nRiYXfhdi=> NGLlcYkzPDZ|M{O1NC=>
MCF7 M2LrOWZ2dmO2aX;uJGF{e2G7 M{\zflAvODYkgKOyNEDPxE1? M1zwOFEh\A>? MV7y[YR2[2W|IITo[UBkdG:wYXygd5Vzfmm4YXygc4YhVUOILUegZ4VtdHNiaX6gcY9vd2yjeXXyJIN2dHS3cnXz Mn7ENlQ3OzN|NUC=
T47D  NXqyXGN7TnWwY4Tpc44hSXO|YYm= MnrINE42KM7:TR?= NFLmV|I1KGR? MofwbY5pcWKrdIOgeJVud3K|cHjldoUh\m:{bXH0bY9v M3PMNVI1PjN|M{Ww
MCF7 NX7ZO2ZwTnWwY4Tpc44hSXO|YYm= M2XlUlAvPeLCk{GwJO69VQ>? MYG0PEBpyqB? M1vFcIlvcGmkaYTzJJRp\SCpYYCgZ4xwe3W{ZTDpckB1cGVid3;1coQhcGWjbHnu[{Bie3OjeR?= MnnCNlQ3OzN|NUC=
MCF7 NEDDWY9HfW6ldHnvckBCe3OjeR?= Mo[4NE8yOCEQvF2= MUmyOEBp NF74VItqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1RQQ>? NUfYcFRxOjR4M{OzOVA>
MDA-MB-231  NHXrPXVHfW6ldHnvckBCe3OjeR?= NUPBc212OC534pETNVAh|ryP MVGzOkBp NF;RV|FqdmirYnn0d{B1cGVibXnndoF1cW:w NIfubGozPDZ|M{O1NC=>

... Click to View More Cell Line Experimental Data

In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02995655 Not yet recruiting Myelodysplastic Syndromes|Acute Myeloid Leukemia|AML|MDS Washington University School of Medicine|Cantex Pharmaceuticals February 28, 2017 Phase 1
NCT02750254 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia Washington University School of Medicine June 27, 2016 Phase 1|Phase 2
NCT02966782 Not yet recruiting Myelodysplastic Syndromes (MDS) AbbVie|Genentech, Inc. March 2017 Phase 1
NCT02959437 Not yet recruiting Advanced Solid Tumors Incyte Corporation February 2017 Phase 1|Phase 2
NCT02942758 Not yet recruiting Acute Myeloid Leukemia University Hospital Regensburg|Anticancer Fund, Belgium|Celgene February 2017 Phase 2
NCT03019003 Not yet recruiting Head and Neck Cancer Massachusetts General Hospital|AstraZeneca February 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Related Antibodies

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID